Skip to main content
main-content

Cardiovascular outcomes

News

14-08-2019 | Gestational diabetes | News

Metformin exposure during pregnancy may impact postnatal growth trajectory

Infants born to mothers with gestational diabetes treated with metformin have lower birthweight, but experience accelerated postnatal growth and have higher BMI in childhood, compared with those whose mothers were treated with insulin, suggest findings from a meta-analysis.

06-08-2019 | Metformin | Highlight | News

Support for metformin cardioprotective effect

Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.

05-08-2019 | Dyslipidemia | News

Very low LDL could be protective in diabetic dyslipidemia

Achieving very low levels of low-density lipoprotein cholesterol while on statin treatment may reduce the risk for cardiovascular disease in people with type 2 diabetes and metabolic dyslipidemia, suggest the results of a large observational study.

Read more

Opinion

22-05-2019 | Sulfonylureas | Editorial | Article

The CAROLINA trial: Make or break for sulfonylureas?

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.

14-11-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

22-11-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

In depth

03-07-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

02-07-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

Journal articles and book chapters

13-12-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

15-10-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

31-08-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

Image Credits